Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib for Steroid Refractory Chronic Graft-Versus-Host Disease
NCT04200365Phase 2Terminated
- Sponsor
- SCRI Development Innovations
- Start
- Jun 2020
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of itacitinib in chronic graft-versus-host disease (cGVHD), sponsored by SCRI Development Innovations. Primary endpoint: Overall Response Rate at 6 months. Started Jun 2020; status: terminated.
02
Drugs
itacitinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT04200365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04200365.